Rapid Blood Test Allows for Earlier Detection of Pregnancy
By LabMedica International staff writers Posted on 07 Sep 2015 |
Image: The AdexusDx hCG early pregnancy testing kit (Photo Courtesy of NOWDiagnostics).
Early detection of pregnancy is important for caregivers in order to avoid certain medications and procedures that could harm a fetus, but unfortunately, clinics are experiencing too many false-negative results from point-of-care urine-based tests.
An immunoassay used for the qualitative detection of human chorionic gonadotropin (hCG) in human whole blood, plasma or serum is now available and the test is used as an early detection aid for pregnancy for health care professionals in a variety of clinical and critical care settings.
The assay has now been Clinical Laboratory Improvement Amendments (CLIA) registered and classified by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). The new hCG test is the first single-step, capillary blood hCG test requiring no equipment to receive FDA 510(k) clearance. The hCG test can detect pregnancy approximately two to eight days earlier than commonly available urine-based tests. The hCG test results are available 10 minutes after the test is used.
The ADEXUSDx hCG Test is a from a product line manufactured by NOWDiagnostics Inc. (Springdale, AR, USA). The patented technology allows physicians to easily and accurately receive results within minutes by using a single drop of capillary or whole blood. Testing is a single-step process that can identify common conditions, illnesses and diseases with the same or better accuracy, sensitivity, specificity and precision as a predicate device in a full-scale laboratory. The diagnostic test kits can be processed in as little as 5 to 15 minutes, onsite in-clinic and by staff technicians and nurses.
Kevin Clark, CEO and president and of NOWDiagnostics Inc., said, “It's too important for the safety of the mother and fetus to not have accurate pregnancy results in our emergency rooms and clinics. Our hCG test can save lives and reduce liability for health care providers. We see a great opportunity to save hospitals and clinics time, money and resources by providing them a lab in the palm of their hands.”
Related Links:
US Food and Drug Administration
NOWDiagnostics Inc.
An immunoassay used for the qualitative detection of human chorionic gonadotropin (hCG) in human whole blood, plasma or serum is now available and the test is used as an early detection aid for pregnancy for health care professionals in a variety of clinical and critical care settings.
The assay has now been Clinical Laboratory Improvement Amendments (CLIA) registered and classified by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). The new hCG test is the first single-step, capillary blood hCG test requiring no equipment to receive FDA 510(k) clearance. The hCG test can detect pregnancy approximately two to eight days earlier than commonly available urine-based tests. The hCG test results are available 10 minutes after the test is used.
The ADEXUSDx hCG Test is a from a product line manufactured by NOWDiagnostics Inc. (Springdale, AR, USA). The patented technology allows physicians to easily and accurately receive results within minutes by using a single drop of capillary or whole blood. Testing is a single-step process that can identify common conditions, illnesses and diseases with the same or better accuracy, sensitivity, specificity and precision as a predicate device in a full-scale laboratory. The diagnostic test kits can be processed in as little as 5 to 15 minutes, onsite in-clinic and by staff technicians and nurses.
Kevin Clark, CEO and president and of NOWDiagnostics Inc., said, “It's too important for the safety of the mother and fetus to not have accurate pregnancy results in our emergency rooms and clinics. Our hCG test can save lives and reduce liability for health care providers. We see a great opportunity to save hospitals and clinics time, money and resources by providing them a lab in the palm of their hands.”
Related Links:
US Food and Drug Administration
NOWDiagnostics Inc.
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form